Corinne Veyret

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial
    Corinne Veyret
    Department of Medical Oncology, Henri Becquerel Center, Rouen, France
    Cancer 107:2535-44. 2006
  2. pmc Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel
    Eva J Kantelhardt
    Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
    BMC Cancer 11:140. 2011

Collaborators

  • Pierre Fargeot
  • Pierre Fumoleau
  • Henri Roche
  • Eva J Kantelhardt
  • Gunter von Minckwitz
  • Daniela Paepke
  • Fred Sweep
  • Manfred Schmitt
  • Christoph Meisner
  • Volker Hanf
  • Christoph Thomssen
  • Martina Vetter
  • Marcus Schmidt
  • Pierre Marie Martin
  • Nadia Harbeck
  • Fritz Jaenicke
  • Doris Augustin

Detail Information

Publications2

  1. ncbi Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial
    Corinne Veyret
    Department of Medical Oncology, Henri Becquerel Center, Rouen, France
    Cancer 107:2535-44. 2006
    ....
  2. pmc Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel
    Eva J Kantelhardt
    Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
    BMC Cancer 11:140. 2011
    ..High-risk node-negative patients should receive chemotherapy. Anthracycline-based regimens are accepted as a standard, the additional benefit of taxanes remains an open question...